Azitra Q3 2026 Earnings Date & Estimates

Azitra (NYSEAMERICAN:AZTR) is a clinical-stage biotechnology company focused on developing microbiome-based therapies for dermatological conditions. The company combines microbiology, genetic engineering and computational tools to identify and develop targeted treatments intended to address diseases affecting the skin.

Azitra’s platform centers on engineered strains of beneficial skin bacteria and biologic compounds designed to deliver therapeutic proteins or otherwise influence the skin’s local environment. Its development programs have focused on conditions including inflammatory skin disorders, rare genetic diseases and treatment-related dermatologic complications. The company has advanced topical product candidates through preclinical and early clinical development, although the availability and status of individual programs may change as development progresses.

Azitra was founded in 2014 and is based in the United States. The company’s research and development activities are directed primarily toward dermatology applications, with potential use in both rare diseases and broader skin-care markets. Publicly available information about its current leadership and geographic commercial operations is limited.